Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab versus continued daratumumab + lenalidomide + dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
jRCT2071250118Phase 3Recruiting
- Sponsor
- European Myeloma Network B.V. (EMN)
- Start
- May 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of linvoseltamab in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network B.V. (EMN). Primary endpoints: MRD-negative CR at 10^-5 per IMWG criteria, MRD-negative CR at 10^-5 by BICR and 2 more. Started May 2026; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2071250118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250118.